Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.58 |
| ▸ | CNR1 | P21554 | 9/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217377 | 0.89 | CNR2 (0.55) | CNR2CNR1TSHR | |
| SCHEMBL14666031 | 0.83 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL1621618 | 0.81 | CNR2 (0.67) | CNR2CNR1TSHREGFR | |
| SCHEMBL10171441 | 0.80 | CNR2 (0.60) | CNR2CNR1EGFR | |
| SCHEMBL10217047 | 0.77 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL10217075 | 0.76 | CNR2 (0.48) | CNR2CNR1ALDH1A1 | |
| SCHEMBL10171440 | 0.75 | CNR2 (0.57) | CNR2CNR1EGFR | |
| SCHEMBL10217376 | 0.74 | CNR2 (0.65) | CNR2CNR1ALDH1A1 | |
| SCHEMBL10221217 | 0.74 | CNR2 (0.58) | CNR2CNR1EGFR | |
| SCHEMBL1621785 | 0.74 | CNR2 (1.00) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8048899-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TSHR 843/4885 |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TSHR 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.